Literature DB >> 6678974

Brain metastasis from melanoma.

T N Byrne, T L Cascino, J B Posner.   

Abstract

Eighty-one patients with brain metastasis from melanoma were identified at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1978 and 1980. Of 78 evaluable patients, 51 (65%) had multiple brain metastases. Of 64 patients with non-contrast CT scans, 29% had hemorrhagic metastases. Leptomeningeal metastases were found in 15 patients. Patients were grouped into three categories: Group 1, multiple brain metastases treated with radiation therapy (RT) (n = 49); Group 2, single brain metastasis treated with RT (n = 17); Group 3, single brain metastasis treated with surgery with or without RT (n = 9). Median survivals for Groups 1, 2 and 3 were 11, 9 and 41 weeks, respectively. Eighty-six percent, 65% and 33% of patients in Groups 1, 2 and 3, respectively, were steroid-dependent until death. Seizures occurred in 38 patients (48%). In 17 (21%), seizures were the first manifestation of metastasis. Of 51 patients not receiving prophylactic anticonvulsants, 37% had seizures. Of 12 patients treated prophylactically, 17% developed seizures. Surgical extirpation should be considered in highly selected patients with brain metastasis from melanoma. Prophylactic anticonvulsants are recommended if there is no contraindication.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678974     DOI: 10.1007/bf00165714

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

1.  Metastatic carcinoma in the central nervous system and dorsal root ganglia. A prospective autopsy study.

Authors:  J L CHASON; F B WALKER; J W LANDERS
Journal:  Cancer       Date:  1963-06       Impact factor: 6.860

2.  A simplification in the use of the NSD concept in practical radiotherapy.

Authors:  C G Orton; F Ellis
Journal:  Br J Radiol       Date:  1973-07       Impact factor: 3.039

3.  Intracranial metastatic malignant melanoma: long-term survival following subtotal resection.

Authors:  M L Bauman; T R Price
Journal:  South Med J       Date:  1972-03       Impact factor: 0.954

4.  Spontaneous regression of metastatic malignant melanoma.

Authors:  W H McCarthy; H M Shaw; G W Milton
Journal:  Clin Oncol       Date:  1978-09

5.  The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system.

Authors:  H R Katz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-07       Impact factor: 7.038

6.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

7.  Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II.

Authors:  R J Carella; R Gelber; F Hendrickson; H C Berry; J S Cooper
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

8.  Radiation therapy for brain metastases.

Authors:  J G Cairncross; J H Kim; J B Posner
Journal:  Ann Neurol       Date:  1980-06       Impact factor: 10.422

9.  Intracranial metastases of malignant melanoma treated by surgery.

Authors:  L Hafström; P E Jönsson; L G Strömblad
Journal:  Cancer       Date:  1980-11-01       Impact factor: 6.860

10.  Computed tomography of virally induced canine brain tumors: a preliminary report.

Authors:  D R Groothuis; M A Mikhael; J M Fischer; J F Pasternak; T Fouts; D D Bigner; N A Vick
Journal:  J Comput Assist Tomogr       Date:  1981-08       Impact factor: 1.826

View more
  38 in total

1.  Seizure prophylaxis and melanoma brain metastases.

Authors:  S A Goldlust; M Hsu; A B Lassman; K S Panageas; E K Avila
Journal:  J Neurooncol       Date:  2012-02-05       Impact factor: 4.130

2.  Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.

Authors:  Emanuela Romano; Michael Scordo; Stephen W Dusza; Daniel G Coit; Paul B Chapman
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

Review 3.  Current management of metastatic brain disease.

Authors:  Tulika Ranjan; Lauren E Abrey
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 4.  Brain metastases: 1995. A brief review.

Authors:  J B Posner
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 5.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

Review 6.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

7.  Malignant melanoma metastasis to brain: role of degradative enzymes and responses to paracrine growth factors.

Authors:  G L Nicolson; M Nakajima; J L Herrmann; D G Menter; P G Cavanaugh; J S Park; D Marchetti
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Cranial irradiation after surgical excision of brain metastases in melanoma patients.

Authors:  J M Skibber; S J Soong; L Austin; C M Balch; R E Sawaya
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

9.  Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.

Authors:  Jeffrey J Raizer; Wen-Jen Hwu; Katherine S Panageas; Andrew Wilton; Drew E Baldwin; Elizabeth Bailey; Caroline von Althann; Lynne A Lamb; Gladys Alvarado; Mark H Bilsky; Philip H Gutin
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

10.  Brain surface invasion and metastasis of murine malignant melanoma variants.

Authors:  G L Nicolson; T Kawaguchi; M Kawaguchi; C Van Pelt
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.